PE20142242A1 - Anticuerpos humanos anti-cd27, metodos, y usos - Google Patents
Anticuerpos humanos anti-cd27, metodos, y usosInfo
- Publication number
- PE20142242A1 PE20142242A1 PE2014001420A PE2014001420A PE20142242A1 PE 20142242 A1 PE20142242 A1 PE 20142242A1 PE 2014001420 A PE2014001420 A PE 2014001420A PE 2014001420 A PE2014001420 A PE 2014001420A PE 20142242 A1 PE20142242 A1 PE 20142242A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- group
- methods
- activity
- human antibodies
- Prior art date
Links
- 102100027207 CD27 antigen Human genes 0.000 abstract 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANO AISLADO CD27 QUE COMPRENDE UNA REGION VARIABLE DE CADENA LIVIANA; QUE CONTIENE: A) UNA SECUENCIA DE AMINOACIDOS DE LA REGION DETERMINANTE DE COMPLEMENTARIEDAD DE CADENA LIGERA 1 ( CDRL1) SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID N� 59-66 Y 158, CDRL2 SELECCIONADO DEL GRUPO QUE CONSISTE EN SEQ ID N� 67-74, CDRL3 SELECCIONADO DEL GRUPO QUE CONSISTE EN SEQ ID N� 75; Y B) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE: CDRH1 SELECCIONADA DEL GRUPO QUE CONSISTE EN SEQ ID N�42-45 Y 161, CDRH2 SELECCIONADO DEL GRUPO QUE CONSISTE EN 46-57, 156 Y 157, CDRH3 DE SEQ ID N� 58. DICHOS ANTICUERPOS SON UTILES PARA DIAGNOSTICAR O TRATAR LA ACTIVIDAD DE ENFERMEDADES Y ESTADOS ASOCIADOS CON LA ACTIVIDAD DE CD27.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611332P | 2012-03-15 | 2012-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142242A1 true PE20142242A1 (es) | 2015-01-08 |
Family
ID=49157853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001420A PE20142242A1 (es) | 2012-03-15 | 2013-03-14 | Anticuerpos humanos anti-cd27, metodos, y usos |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US9102737B2 (es) |
| EP (1) | EP2825200A4 (es) |
| JP (1) | JP6487839B2 (es) |
| KR (1) | KR102153374B1 (es) |
| CN (1) | CN104284678B (es) |
| AR (1) | AR090356A1 (es) |
| AU (1) | AU2013232087B2 (es) |
| BR (2) | BR112014022812A2 (es) |
| CA (1) | CA2867299C (es) |
| CL (1) | CL2014002416A1 (es) |
| CO (1) | CO7071095A2 (es) |
| CR (1) | CR20140415A (es) |
| EA (1) | EA030828B1 (es) |
| EC (1) | ECSP14018641A (es) |
| GT (1) | GT201400193A (es) |
| HK (1) | HK1206251A1 (es) |
| JO (1) | JO3787B1 (es) |
| MX (1) | MX363946B (es) |
| MY (1) | MY175224A (es) |
| NZ (1) | NZ629697A (es) |
| PE (1) | PE20142242A1 (es) |
| PH (2) | PH12014502011B1 (es) |
| SG (2) | SG11201405437QA (es) |
| TW (2) | TW201730214A (es) |
| UA (1) | UA121844C2 (es) |
| UY (1) | UY34680A (es) |
| WO (1) | WO2013138586A1 (es) |
| ZA (2) | ZA201407440B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602892A (en) | 2010-04-13 | 2014-08-29 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
| EP2686347B1 (en) | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| WO2014140374A2 (en) * | 2013-03-15 | 2014-09-18 | Novo Nordisk A/S | Monovalent cd27 antibodies |
| TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| FR3025517B1 (fr) * | 2014-09-10 | 2016-12-23 | Repropharm | Ligands potentialisants de la bioactivite des gonadotrophines |
| WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
| EP3355921A4 (en) * | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | ANTAGONIST ANTIBODIES SPECIFICALLY BINDING TO HUMAN CD40 AND METHODS OF USE |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| AU2016341409B2 (en) * | 2015-10-23 | 2021-02-25 | Apogenix Ag | Single-chain CD27-receptor agonist proteins |
| WO2017117384A1 (en) | 2015-12-31 | 2017-07-06 | Development Center For Biotechnology | Anti-vegfr antibody and uses thereof |
| AU2017252527A1 (en) | 2016-04-18 | 2018-11-08 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗ｐｄ－ｌ１抗体 |
| JOP20190055A1 (ar) * | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| US20190225698A1 (en) * | 2016-09-29 | 2019-07-25 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-cd27 antibody, antigen-binding fragment thereof, and medical use of same |
| EP4467565A3 (en) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| BR112019012950A2 (pt) | 2016-12-23 | 2019-11-26 | Macrogenics Inc | molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo |
| EP3621981A2 (en) | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| EP3648757A4 (en) * | 2017-07-03 | 2020-11-25 | Development Center for Biotechnology | ANTI-VEGFR ANTIBODIES AND ITS USES |
| WO2019037131A1 (zh) * | 2017-08-25 | 2019-02-28 | 深圳市博奥康生物科技有限公司 | 一种cd27真核表达载体的构建及其高表达细胞株的制备 |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| JP7359390B2 (ja) * | 2018-02-09 | 2023-10-11 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| RU2020133807A (ru) * | 2018-03-28 | 2022-04-28 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Антитело к cd27, его антигенсвязывающий фрагмент и их применение в медицине |
| CN112292399A (zh) * | 2018-04-04 | 2021-01-29 | 百时美施贵宝公司 | 抗cd27抗体及其用途 |
| CN111971303B (zh) * | 2018-04-13 | 2022-05-17 | 苏州丁孚靶点生物技术有限公司 | 抗cd27抗体及其用途 |
| CA3097369A1 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| KR20210008502A (ko) | 2018-05-11 | 2021-01-22 | 크리스퍼 테라퓨틱스 아게 | 암을 치료하기 위한 방법 및 조성물 |
| MA52889A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| WO2020185952A1 (en) * | 2019-03-11 | 2020-09-17 | xCella Biosciences, Inc. | Cd27-binding antibodies and uses thereof |
| BR112021021542A2 (pt) | 2019-04-30 | 2022-04-19 | Crispr Therapeutics Ag | Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| KR20220016452A (ko) * | 2019-05-24 | 2022-02-09 | 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 | 항-csf1r 항체, il10 융합 단백질, 및 이들의 이용 |
| EP4022091A1 (en) * | 2019-08-30 | 2022-07-06 | Janssen Biotech, Inc. | B-cell maturation complex car t construct and primers |
| JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
| TW202208427A (zh) * | 2020-05-06 | 2022-03-01 | 德商因夫萊亞斯有限公司 | 人源化抗ｃ５ａ抗體 |
| CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| CN112646029B (zh) * | 2020-12-30 | 2022-07-29 | 深圳清华大学研究院 | 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒 |
| JP2024512669A (ja) | 2021-03-31 | 2024-03-19 | フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド | タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用 |
| CN113444178B (zh) * | 2021-06-17 | 2022-12-02 | 南京蓝盾生物科技有限公司 | 抗cd70内化的抗体、抗体偶联物及其应用 |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| AU2023236289A1 (en) | 2022-03-15 | 2024-08-15 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| CN115165829A (zh) * | 2022-06-29 | 2022-10-11 | 上海交通大学 | 一种定量分析系统性红斑狼疮免疫细胞与功能蛋白的方法及其应用 |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN118667002A (zh) * | 2023-03-16 | 2024-09-20 | 上海赛金生物医药有限公司 | 抗cd27单克隆抗体及其应用 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| CN119661718B (zh) * | 2025-02-20 | 2025-06-06 | 杭州华大生命科学研究院 | 一种抗cd27纳米抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| KR100249937B1 (ko) | 1991-04-25 | 2000-04-01 | 나가야마 오사무 | 인간 인터루킨-6 수용체에 대한 재구성 인간 항체 |
| US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| EP1263788A2 (en) | 2000-02-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| US6982361B1 (en) | 2000-02-25 | 2006-01-03 | The Regents Of The University Of California | Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| WO2003025019A1 (en) | 2001-09-20 | 2003-03-27 | Alexion Pharmaceuticals, Inc. | Anti-pdgf antibodies and methods for producing engineered antibodies |
| AU2003210266A1 (en) | 2002-02-14 | 2003-09-04 | Bioinvent International Ab | Treatment, diagnosis and imaging of disease |
| AU2004213432A1 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Novel therapeutic targets in cancer |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| BRPI0611220A2 (pt) | 2005-06-02 | 2010-08-24 | Astrazeneca Ab | anticorpos direcionados para cd20 e usos dos mesmos |
| GB0620894D0 (en) | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| WO2009085462A1 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
| EP2090320A1 (en) | 2008-02-15 | 2009-08-19 | Helmholtz-Zentrum für Infektionsforschung GmbH | Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof |
| CN102007147B (zh) * | 2008-06-30 | 2014-11-05 | 协和发酵麒麟株式会社 | 抗cd27抗体 |
| JP5828765B2 (ja) * | 2009-12-29 | 2015-12-09 | 協和発酵キリン株式会社 | 抗ｃｄ２７抗体 |
| NZ602892A (en) * | 2010-04-13 | 2014-08-29 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
| WO2012004367A1 (en) * | 2010-07-09 | 2012-01-12 | N.V. Organon | Agonistic antibody to cd27 |
-
2013
- 2013-03-14 JO JOP/2013/0072A patent/JO3787B1/ar active
- 2013-03-14 JP JP2015500608A patent/JP6487839B2/ja active Active
- 2013-03-14 WO PCT/US2013/031314 patent/WO2013138586A1/en active Application Filing
- 2013-03-14 NZ NZ629697A patent/NZ629697A/en unknown
- 2013-03-14 MY MYPI2014702561A patent/MY175224A/en unknown
- 2013-03-14 SG SG11201405437QA patent/SG11201405437QA/en unknown
- 2013-03-14 EA EA201491700A patent/EA030828B1/ru unknown
- 2013-03-14 CA CA2867299A patent/CA2867299C/en active Active
- 2013-03-14 SG SG10201710574UA patent/SG10201710574UA/en unknown
- 2013-03-14 PE PE2014001420A patent/PE20142242A1/es active IP Right Grant
- 2013-03-14 CN CN201380025446.3A patent/CN104284678B/zh active Active
- 2013-03-14 MX MX2014011100A patent/MX363946B/es active IP Right Grant
- 2013-03-14 KR KR1020147028682A patent/KR102153374B1/ko active Active
- 2013-03-14 BR BR112014022812A patent/BR112014022812A2/pt not_active Application Discontinuation
- 2013-03-14 HK HK15106811.7A patent/HK1206251A1/xx unknown
- 2013-03-14 BR BR122020002414-3A patent/BR122020002414B1/pt active IP Right Grant
- 2013-03-14 AU AU2013232087A patent/AU2013232087B2/en active Active
- 2013-03-14 EP EP13761537.3A patent/EP2825200A4/en active Pending
- 2013-03-14 UA UAA201411147A patent/UA121844C2/uk unknown
- 2013-03-15 AR ARP130100851A patent/AR090356A1/es active IP Right Grant
- 2013-03-15 TW TW106102009A patent/TW201730214A/zh unknown
- 2013-03-15 US US13/835,518 patent/US9102737B2/en active Active
- 2013-03-15 TW TW102109158A patent/TWI576354B/zh active
- 2013-03-15 UY UY0001034680A patent/UY34680A/es not_active Application Discontinuation
-
2014
- 2014-09-09 PH PH12014502011A patent/PH12014502011B1/en unknown
- 2014-09-09 CR CR20140415A patent/CR20140415A/es unknown
- 2014-09-12 CL CL2014002416A patent/CL2014002416A1/es unknown
- 2014-09-12 EC ECIEPI201418641A patent/ECSP14018641A/es unknown
- 2014-09-12 CO CO14202427A patent/CO7071095A2/es unknown
- 2014-09-12 GT GT201400193A patent/GT201400193A/es unknown
- 2014-10-14 ZA ZA2014/07440A patent/ZA201407440B/en unknown
-
2015
- 2015-02-06 ZA ZA2015/00887A patent/ZA201500887B/en unknown
- 2015-07-02 US US14/790,144 patent/US9683046B2/en active Active
-
2017
- 2017-05-16 US US15/596,609 patent/US10301392B2/en active Active
- 2017-10-19 PH PH12017501908A patent/PH12017501908B1/en unknown
-
2019
- 2019-04-12 US US16/382,645 patent/US10689453B2/en active Active
-
2020
- 2020-05-19 US US16/878,209 patent/US11732050B2/en active Active
-
2023
- 2023-06-29 US US18/216,074 patent/US20240141055A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| AR086044A1 (es) | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| JP2020500538A5 (es) | ||
| MX2020013068A (es) | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| PE20171244A1 (es) | Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit) | |
| NZ610153A (en) | Novel anti-dr5 antibody | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR066164A1 (es) | Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| WO2012045481A3 (en) | Antibody targeting osteoclast-related protein siglec-15 | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| RS52345B (en) | ANTI-IL-23P19 ANTIBODY MANUFACTURED BY GENETIC ENGINEERING | |
| AR087405A1 (es) | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| NZ603488A (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| PE20150945A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |